key: cord-343127-n3fs8ph8
authors: Pousa, Pedro A.; de Mendonça, Tamires S.C.; Oliveira, Eduardo A.; e Silva, Ana Cristina Simões
title: Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations
date: 2020-09-22
journal: J Pediatr (Rio J)
DOI: 10.1016/j.jped.2020.08.007
sha: 
doc_id: 343127
cord_uid: n3fs8ph8

OBJECTIVE: The aim of this review was to summarize the most common extrapulmonary manifestations in pediatric patients with COVID-19, as well as to discuss clinical, epidemiological, and pathophysiological aspects of these clinical presentations in children. SOURCE OF DATA: An extensive search of literature was performed in order to identify pediatric cases with extrapulmonary manifestations between January 1, 2020 and June 21, 2020. Generic keywords, such as “Novel coronavirus” or “Novel coronavirus 2019” or “2019 nCoV” or “COVID-19” or “SARS-CoV-2” were searched on PubMed database, associated either with age filters or generic pediatric terms. SUMMARY OF FINDINGS: A total of 28 articles, including 199 patients, were considered suitable to review and data extraction. The main findings were summarized in tables. The main non-pulmonary manifestations in pediatric patients, in decreasing order of frequency, were gastrointestinal, renal, cardiovascular, neurological, hematological and lymphatic, cutaneous, hepatic, ocular, olfactory, and gustatory. Multisystem impairment and Kawasaki-like disease were also described. CONCLUSIONS: Differences in immune response of children and variations of tissue expression of angiotensin converting enzyme 2, the virus receptor, are likely to influence clinical, epidemiological, and pathophysiological patterns of the disease.

Study." To minimize any ineffectiveness of the age filters, a second search was made by disabling the filters and adding the terms "children", "infant", "neonate" and "adolescent" to the generic terms specified in the first search.

One author extracted data from the selected studies and included the findings in Table 1 .

Then, a second author reviewed all selected studies and the table to avoid any errors in data extraction.

A. Study identification: First author, publication date, country, and type of study; B. Participants: Age, gender, and sample size; C. Variables: Source of SARS-CoV-2 exposure, signs and symptoms, co-morbidities and co-infections, complications during the disease, main treatment, and outcome.

To elaborate Table 2 , one author extracted data from Table 1 and summarized into the following listed below. Then, a second author double-checked all data included to avoid any errors in extraction.

A. Signs and symptoms were classified by organs and systems affected; B. Number of times the symptom or sign was described;

C. Percentage of symptom/sign concerning each organ/system;

One author selected potential articles based on the study title and abstract. Whenever a study appeared to meet the inclusion criteria, the authors obtained full text. Once the search was completed and full articles were obtained, two authors independently made the definitive inclusion of the article by reviewing the text of the selected studies. Any differences between authors' selections were solved by discussion between them. If these authors were not able to achieve a consensus, a third author was consulted. One study [13] did not fit the inclusion criteria described below, since two out of 21 participants did not test positive for SARS-CoV-2. However, the authors in consensus decided to include the article due to its relevance and minor impact on qualitative study reliability.

patients, [16, 20] representing a frequent complication. Cardiac manifestations were often described as alterations in myocardial enzymes, [18, 24, 34] tachycardia, [26, 27, 34, [36] [37] [38] and shock, [16] with eight and 25 presentations, respectively. Vascular manifestations included aneurysms [26] and ischaemic infarctions [15] were identified and associated with obesity. Cardiac damage and dysfunction was observed in five patients. [30] Neurological manifestations were frequently described as neurocognitive symptoms, including headache, irritability, lethargy, and somnolence. [13] [14] [15] [16] 23, 24, 26, 29, 31, 33] Axial hypotonia, [22] generalized hypertonia,[23] and muscular pain [39] indicated the presence of neuromuscular manifestations.

Inflammatory markers were often elevated and described as a multisystemic manifestation, sometimes leading to multiorgan dysfunction complications. [13, 23, 31] Hematologic and lymphatic manifestations were also reported, with variations in leukocytes, [18, 24, 37] lymphocytes, [17, 19, 24] neutrophil count, [17, 18, 40] and erythrocyte sedimentation rate. [31] Twelve cases of lymphadenopathy were described. [13] Kawasaki-like disease (KD) and cutaneous manifestations were described and often associated (Fig. 3) . [13, 27] Dermatologic presentations were defined as skin rashes, [13, 15, 26, 27, 31] perineal or facial desquamation, [13] erythemas [22] and exanthems. [19] Complete Kawasaki disease and KD shock syndrome was confirmed in 21 and 28 patients, respectively. [13, 16, 27] Bilateral conjunctival injections were described in 17 patients and were all associated with KD. Other ocular manifestations included watery eye discharge,[23] conjunctivitis, [15] and periorbital erythema. [29] Other isolated presentations were also reported, such as anosmia, [13, 39] ageusia, [39] arthralgia. [13] Full cases description and prevalence rates are described in Tables 1 and   2 , respectively.

In the respiratory route infection, protein S, expressed in the viral envelope, interacts with the membrane-bound ACE2 that is expressed in type I and type II alveolar pneumocytes.

This link stimulates a clathrin-dependent endocytosis, creating a low pH endosome containing the protein S and ACE2 complex inside the host cell. [4] This infection mechanism explains the primary lung manifestations, due to the presence of viral particles, infiltration of inflammatory cells and cytopathic effects on lung cells. [41] However, ACE2 is not only expressed on type I and type II pneumocytes.

Hamming et al. [42] had investigated the tissue distribution of ACE2 in healthy human

organs. An interesting result found in that study was the high and strong presence of ACE2 in epithelial cells of the lung, the small intestine, and the kidney. ACE2 was also expressed in vascular endothelial cells, in smooth muscle cells, in the basal epidermal layer of in the skin, and in the oral and nasal mucosa. These results suggest other viral transmission routes related to ACE2 expression. Furthermore, the ubiquitous expression of ACE2 in human body explains the great variability of extrapulmonary manifestations on COVID-19.

Additionally, as a result of the endocytosis of the SARS-CoV-2 along with ACE2, the membrane-bound enzyme is reduced in several organs and system. [43] This downregulation affects the entire RAAS, which is responsible for the blood pressure control and several organ homeostasis . [5] Therefore, COVID-19 is conceived as a systemic disease, being RAAS molecules critical for pathophysiological mechanisms. [6] Hence, SARS-CoV-2 infection may be considered a systemic condition with pulmonary involvement rather than a respiratory disease with extrapulmonary manifestations.

As previously mentioned, children are less infected and less affected by SARS-CoV-2, unlike other respiratory diseases. The milder presentation of COVID-19 can be related to the immature immune system memory of children, as they are yet building their pool of B

and T-cells. Therefore, they are more prepared to deal with completely novel antigens, such as SARS-CoV-2, than elderly people, as they present lower amounts of lymphocytes. There are two populations of memory B-cells: CD27 Bright and CD27 Dull . CD27 Bright is known for producing specific antibodies against the antigen, while CD27 Dull synthesizes antibodies with wide range of activity. In children, CD27 Dull prevails over CD27 Bright , explaining their higher ability to face new diseases. In elderly individuals, the inverse happens. [12] The mechanisms of this innate immune system were suggested in the study by Paki and Iwasaki; [44] Interferon (IFN) response is an adaptive form of the immune system and its timing can vary with viral load and/or genetic differences. An early IFN response can lead to rapid viral clearance before its replication, resulting in milder diseases. Delayed IFN response can enable viral persistence, increase levels of inflammatory markers such as IL-6, and cause severe cases. IFN induction can be delayed and minimized in older hosts, explaining the increasing vulnerability with aging. As shown in Table 2 , GI manifestations are the most common extrapulmonary signs and symptoms of SARS-CoV-2 infection in pediatric patients. Digestive symptoms are presented in 8-10% of pediatric cases of COVID-19, including diarrhea, abdominal pain and discomfort and vomiting. [45] A systematic review observed that the prevalence of GI symptoms was 9.6% in children and 9.7% in adults, a difference that is not statistically significant. A review performed by Tian et al. [46] found, that when compared with adults, children present similar percentages of diarrhea, but a considerable higher rate of vomiting. The implications of these findings will be discussed later on this article.

As previously mentioned, the ACE2 receptor, presented in type I and II pneumocytes, is a crucial component for viral endocytosis during SARS-CoV-2 infection. In addition, epithelial cells of the small intestine is another tissue that highly express ACE2 in cell membrane, [42] creating another potential region for SARS-CoV-2 infection and enteric manifestations of COVID-19. The pathophysiology of these GI symptoms is not well elucidated, but some potential mechanisms are described in a study of Ye et al. [47] The most logical mechanism relates the high expression of ACE2 in the epithelial cells of small intestine that may cause a direct viral infection into the bowel. However, this hypothesis remains speculative, as one study found that SARS-CoV-2 was not always detected in stool samples of COVID-19 patients with GI manifestations.

Although scientific data did not describe renin angiotensin system (RAS) primarily affecting the intestine, this system regulates the homeostasis of intestinal amino acids, the expression of antimicrobial peptides, the and ecology of the gut microbiome. [48] Some studies speculate that the downregulation of ACE2 expression in the epithelial cells of the intestine may affect the absorption of tryptophana peptide that belongs to a pathway that regulates the antimicrobial peptides expression and, therefore, the composition of the intestinal flora. [47] Therefore, any dysregulation of this pathway could lead to GI symptoms, such as diarrhea.

Other mechanisms were also discussed in the study by Ye et al., [47] including side effects of antibiotics and the establishment of a gut-lung axis that would allow a immune reaction of a lung infection to be also present in the bowel, causing diarrhea and intestinal immune damage.

J o u r n a l P r e -p r o o f

As previously mentioned in this article, no significant difference between children and adults regarding the prevalence of GI symptoms was found, suggesting that both groups are equally susceptible to these manifestations. However, in 54% of adults, GI symptoms were reported to be associated with more severe/critical illness, [49] while Tian et al.

found that, out of 57 children, only one was critically ill with GI presentations. Thus, despite the fact that these groups quantitatively present the same rate of GI symptoms, children appear to exhibit GI symptoms even with less severe illness.

A recent study by Vuille-dit-Bille et al. [50] demonstrated a positive correlation of ACE2 expression in the small intestine and age, with increased ACE2 mRNA expression with aging. Therefore, children might express less ACE2 receptors compared with older patients, being more vulnerable to ACE2-downregulation of the tryptophan pathway, leading to more susceptibility of diarrhea. Hence, the present authors speculate that, although children and adults have similar rates of GI symptoms, children GI symptoms are usually associated as a primary response of SARS-CoV-2 infection, due to this minor expression of ACE2, and represent milder symptoms. Additionally, one study showed that inflammatory cytokines IL-6, IL-10, and TNF-alpha were intensively elevated in adult patients with diarrhea, [51] and related to cytokine storm and multi-organ damage.

Thus, the present authors also suspect that most severe GI presentations in adults may be caused by a secondary response of systemic inflammation triggered by SARS-CoV-2.

Liver injury is another extrapulmonary manifestation of COVID-19, being described as any liver damage presented during the disease progression. This manifestation often occurs in more severe cases rather than mild presentations. [52] Two important biochemical markers of liver injury are increased serum levels of ALT and AST enzymes. Children are susceptible to liver injury, as shown by a meta-analysis of 551 laboratory-confirmed pediatric COVID-19 patients reporting that 9% (35/290) presented increased ALT and 18% (58/280), high levels of AST. [53] The mechanism of SARS-CoV-2 liver damage is not clearly elucidated; it can be either resulted from direct SARS-CoV-2 infection of hepatic cells or drug induced liver injury. Some possible mechanisms described by Sun et al. [52] are: To date, there is no scientific data to elucidate whether children are equally susceptible to liver damage as adults.

A meta-analysis including pediatric patients with SARS-CoV-2 infection conducted by Zhang et al. [53] demonstrated that 5% (22/139) had increased urea and 4% (48/184) had increased creatinine. A cohort study by Stewart et al. [54] showed a frequency of increased serum creatinine in 46% (n = 24), and 29% (n = 15) of hospitalised patients that meet the diagnosis criteria for acute kidney injury. Out of these 15 inpatients with AKI, 93% (n = 14) were admitted to the pediatric intensive care unit (PICU) and 73% (n = 11) were associated with with multisystem inflammatory syndrome in children (MIS-C) temporarily associated with SARS-CoV-2. These data suggest that AKI may not have a high prevalence in pediatric patients with COVID-19. However, when present, AKI may be the main cause of critical illness in pediatric patients, requiring PICU admission.

As previously mentioned in this article, ACE2 receptors play a critical role in COVID-19 pathophysiology, due to the high affinity of the SARS-CoV-2 protein S to membranebound ACE2. [4] Histologic studies have shown that ACE2 expression is about 100 times greater in the kidneys compared to the lungs, [55] the main pathway for viral infection.

Therefore, it is reasonable to predict that the kidney may be vulnerable to SARS-CoV-2 infection, resulting in an injury caused by the direct cytopathic effect of the viral infection. [56] A renal post-mortem histopathological analysis of 26 adult patients with COVID-19 showed a prominent proximal acute tubular injury (ATI) associated with the loss of brush border. Interestingly, it is known that the ACE2 is highly expressed in the brush border of tubular cells and some coronavirus-like particles were found in the renal proximal tubular epithelium, [42] supporting the cytopathic mechanisms of kidney injury.

As well as this cytopathic mechanism, a systemic condition is another potential mechanism for kidney injury. Cytokine release syndrome (CRS) is being described in J o u r n a l P r e -p r o o f pediatric cases of COVID-19 [57] and might be a cofactor of renal manifestations. Hirano and Murakami described the potential role of ACE-AngII-AT1R axis dysregulation of the RAS during the later phase of infection leading to downregulation of ACE2 that causes CRS, characterized by high expression of IL-6 and TNF. [41, 59] Intrarenal inflammation, increased vascular permeability, volume depletion, and cardiomyopathy, caused by these cytokines, might also lead to kidney failure. [56] Other minor potential mechanisms of kidney injury are being identified, including systemic effects of septic shock and the deposition of immune-complexes in the kidney. [56] Pathophysiological considerations

There is few available data that elucidates pathophysiological differences between adults and children. Vinturache et al. [58] observed greater expression of the AT1R and the AT2R in kidneys and vasculature in the course of fetal life than at any other time during the lifespan in response to cardiovascular and renal demands. Ang II can bind to both receptors. As previously mentioned, the binding of Ang II to AT1R is associated to proinflammatory activity and cytokine release. [41, 59] In turn, the binding of Ang II to AT2R triggers vasodilatory effects, anti-inflammatory actions, and natriuresis. [60] Hence, AT1R expression leads to inflammatory effects, while AT2R mediates protective effects.

This study has shown that the decline rate of expression of AT2R is greater than that of AT1R, causing a predominance of AT1R over AT2R with aging. Therefore, children might present less severe cases of kidney injury associated with COVID-19 due to this greater expression of AT2R than adults. However, further studies on ACE2 expression and other RAS molecules concentrations in children are needed.

As shown in Tables 1 and 2, some pediatric patients presented cardiovascular manifestations, such as tachycardia, increased myocardial enzymes, cardiac injury, and myocardial damage. The literature also reports acute myocardial injury and arrhythmias. [61] In adults, elevated troponin was present in myocarditis, and myoglobin and muscle enzymes were elevated due to COVID-19-associated muscular injury. These No data on the pathophysiological and clinical differences of pediatric patients was retrieved in the literature.

As shown, neurological signs and symptoms are being observed in pediatric SARS-CoV-2 infection. The main clinical manifestations found in the present study are neurocognitive symptoms, which include headache, irritability, and lethargy. Myalgia and other isolated symptoms were found and described in Table 2 , suggesting neuromuscular involvement.

Studies have shown the presence of ACE2 in the nervous system, making these neurological manifestations possible, also due to direct cytopathic effect. Reports indicate the detection of SARS-CoV-2 RNA in cerebrospinal fluid (CSF), confirming the viral presence and activity in central nervous system. Other mechanisms may also cause neural damage, such as hypoxic injury and immune response. [64] Neurologic manifestations in younger children are not always documented, due to difficulties arising from the undeveloped communication that makes the diagnosis harder and subjective. However, physicians and pediatricians should consider COVID-19 as a differential diagnosis of neurologic manifestations in children.

According to the systematic review by Zhang Gupta et al. suggested that the mechanisms for lymphopenia are direct viral entry, leading to cytopathic effects on lymphocytes, apoptosis-mediated lymphocytes depletion, and inhibition of lymphocytes proliferation due to lactic acid effects. An increase in leukocyte count may be induced by hyperinflammatory response to SARS-CoV-2 infection or other bacterial infections. [66] The available data are not sufficient to establish pathophysiological mechanisms that explain differences of these laboratorial findings between adults and children.

Coagulation disorders are a usual complication in adult patients, [67] but no pediatric reports were retrieved. D-dimer levels were elevated in 29.3% adult patients [65] and in 12% of children. [53] The mechanisms behind COVID-19-associated coagulopathy are not fully elucidated, but it is suspected that cytokine storm activates a thromboinflammatory pathway that can lead to abnormalities in coagulation. [68] 

Kawasaki disease is a self-limited acute vasculitis presented in 0.01% of children. The first target of this disease is medium-sized muscular arteries, but several vessels can be affected, such as the coronary arteries. Unlike other vasculitis, KD progression is similar to infectious diseases, with rash, mucosal inflammation, and limb alterations. [69] Although the etiology of Kawasaki disease remains unknown, pathologic, epidemiologic, ultrastructural and immunologic evidence may suggest that an infectious agent leads to a sequence of events causing the disease. In addition, antibiotic treatment failure supports the hypothesis that the etiological agent of KD is not a bacterial pathogen. [70] However, several studies over many decades until 2008 were unable to connect a microorganism to this disease, showing that no known infectious agent can be considered the cause of KD. [71] Due to HCoV-NH, the connection between SARS and KD was already studied, [72] suggesting that KD and coronaviruses infection are associated. Between General Pediatric Unit of Hospital Papa Giovanni XXIII (Bergamo, Italy). Meanwhile, between February 18 and April 20, 2020, ten patients were diagnosed with the disease in this same hospital. Interestingly, eight out these ten patients presented a positive IgM and/or IgG test for SARS-CoV-2. [73] This recent case series reports that six patients had cardiac involvement, five exhibited Kawasaki disease shock syndrome and five presented macrophage activation syndrome, while in the first cohort of 19 patients only two patients had cardiac involvement. These findings suggest that KD in COVID-19 patients result in more severe complications.

In April 2020, an alarming warning was made by the National Health Service in England 63] respectively 92% and 80% of pediatric patients with MIS-C present GI symptoms. Moreover, the latter study [63] reported only 27% rate of respiratory symptoms of SARS-CoV-2-associated MIS-C, suggesting that MIS-C is predominantly reported with GI rather than respiratory symptoms. Furthermore, MIS-C laboratory findings include leukopenia and extremely elevated levels of ventricular natriuretic peptide, while these alterations are not found in KD's patients. [74] Coronary aneurysms are a typical finding of KD, while reports of this presentation are rare in MIS-C. [69, 74] Previousl epidemiological reports suggest that the mean age of children with KD is 2 years, with few reports beyond late childhood, while MIS-C can affect older children and adolescents. [69] Data implies that Asian children are more prone to have KD, and African children are more susceptible to MIS-C.[62, 63, 74] The distinction between KD or MIS-C can be hard to make, leading to misdiagnose. In the present review, several cases of MIS-C and other severe undefined 

Cutaneous manifestations are related not only to SARS-CoV-2 infection, but also to several other infectious diseases, such as toxic shock syndrome, meningococcemia, rickettsial diseases, measles, and scarlet fever. [76] In the present study, 19 manifestations of dermatologic symptoms were observed, including skin rash, mottling, exanthema, erythema, periorbital erythema, and peritoneal or facial desquamation. These skin changes are rarely observed, but they can still go unnoticed due to lack of attention, which raises concern about COVID-19 transmission by misdiagnosed asymptomatic children. [77] The physiopathological mechanism of these lesions remains poorly understood. A review by Kaia et al. indicates two major groups, related to two distinct possible mechanisms. One is related to the immune response to viral nucleotides, similar to viral exanthemas. The other one relates cutaneous eruptions to systemic consequences of COVID-19, such as vasculitis and thrombotic vasculopathy. [78] The present authors speculate that children can be less susceptible to the first mechanism, due to differences in the innate immune system.

Anosmia and ageusia are common symptoms of COVID-19 in adults, [79] which can be attributable to an easier self-diagnosis. However, in children, the description of the absence of smell and taste may be difficult and hinders diagnosis. Additionally, some cases of anosmia and ageusia are described in the present review, but in a very small sample when compared with adults.

A recent study by Brann et al. [80] showed that ACE2 and a protease involved in the viral endocytosis called TMPRSS2 are expressed in the olfactory mucosa, but not (or weakly) in the olfactory receptors neurons. Additionally, anosmia symptoms usually disappear within 1-2 weeks, [81] which exclude neural damage as a cause of the lack of smell and suggest a non-neural cause of anosmia.

The mechanism of SARS-CoV-2 ageusia remains speculative. Retrospective studies from MERS and SARS-CoV suggest that coronaviruses occupy binding sites of sialic acid on taste buds and this can lead to degradation of gustatory particles. Other possibility of lack of taste may be attributable to the simultaneous manifestation of anosmia, as these two sensory systems are associated. [81] Pathophysiological considerations These potential mechanisms described in literature are insufficient to fully explain any pathophysiological differences for these manifestations between children and adults.

However, it is known that children have lower expression of ACE2 in the oral and nasal mucosa.

[82] The present authors suspect that this lower expression of ACE2 might be extended to the non-nervous olfactory tissue and this could explain the lower prevalence of anosmia in kids. Supporting this idea, a recent study of animal models has shown that ACE2 and TMPRSS2 expression in animals increase with aging. However, this remains highly speculative, and histological studies are necessary to elucidate this hypothesis.

Ocular involvement is rarely reported in both adult and pediatric cases of COVID-19; [64] only three symptoms were retrieved in the literature researched: watery eye discharge, periorbital erythema and conjunctivitis. In addition, both ACE2 and TMPRSS2 are expressed in human ocular surface, explaining ocular susceptibility to direct cytopathic effect of SARS-CoV-2 infection. RAS involvement should also be considered, as the eye presents its own RAS molecules in the aqueous humor dynamics, [83] 

The authors declare no conflicts of interest. 

Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan

Situation Report -183. World Health Organization

pdf?sfvrsn = b3869b3_2 3. WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade

Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies

Covid-19: the renin-angiotensin system imbalance hypothesis

Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Is the kidney a target of SARS

The immune system of children: the key to understanding SARS-CoV-2 susceptibility?

Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19

prospective observational study

Fatal outcome of COVID-19 disease in a 5-month infant with comorbidities

Hyperinflammatory shock in children during COVID-19 pandemic

Characteristics, cardiac involvement, and outcomes of multisystem inflammatory disease of childhood (MIS-C) associated with SARS-CoV-2 infection

Anal swab findings in an infant with COVID-19

Special issues for coronavirus disease 2019 in children and adolescents

SARS-CoV-2 infection in children in Parma

Renal dysfunction in hospitalised children with COVID-19

Managing COVID-19-positive maternal-infant dyads: an Italian experience

Atypical presentation of COVID-19 in young 24

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children

Septic shock presentation in adolescents with COVID-19

Toxic shock-like syndrome and COVID-19: a case report of multisystem inflammatory syndrome in children

Novel coronavirus infection in newborn babies aged < 28 days in China

Febrile infant

Acute myocardial injury: a novel clinical pattern in children with COVID-19

Cutaneous manifestations in COVID-19: a skin rash in a child

Horizontal transmission of severe acute respiratory syndrome coronavirus 2 to a premature infant: multiple organ injury and association with markers of inflammation

Tetralogy of Fallot palliation in a COVID-19 positive neonate

A 55-day-old female infant infected with 2019 novel coronavirus disease: presenting with pneumonia, liver injury, and heart damage

Hematuria associated with SARS-CoV-2 infection in a child

Late-onset neonatal sepsis in a patient with COVID-19

COVID-19) infection: a case report and review of literature

Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report

Thalassemic child presenting with anosmia due to COVID-19

infection in a paucisymptomatic infant: raising the index of suspicion in epidemic settings

The cytokine storm and COVID-19

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Type I and type III interferons -induction, signaling, evasion, and application to combat COVID-19

COVID-19 in children: an ample review

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19

ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation

Epidemiological, clinical and J o u r n a l P r e -p r o o f virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

SARS-CoV-2 receptor ACE2 gene expression in small intestine correlates with age

Diarrhea and altered inflammatory cytokine pattern in severe coronavirus disease 2019: impact on disease course and in-hospital mortality

COVID-19 and liver disease

What we know so far about coronavirus disease 2019 in children: a meta-analysis of 551 laboratory-confirmed cases

Renal dysfunction in hospitalised children with COVID-19

Kidney disease is associated with in-hospital death of patients with COVID-19

The kidney in COVID-19: protagonist or figurant?

Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department

Angiotensin type 1 and type 2 receptors during ontogeny: cardiovascular and renal effects

COVID-19: a new virus, but a familiar receptor and cytokine release syndrome

The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease

Cardiovascular disease and COVID-19

Multisystem inflammatory syndrome in U.S. children and adolescents

Multisystem inflammatory syndrome in children in New York State

Extra-respiratory manifestations of COVID-19

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

Extrapulmonary manifestations of COVID-19

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study

COVID-19, coagulopathy and venous thromboembolism: more questions than answers

Rheumatic Disease Clinics of North America

Is Kawasaki disease an infectious disorder?

Searching for the cause of Kawasaki disease -cytoplasmic inclusion bodies provide new insight

Association between a novel human coronavirus and Kawasaki disease

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

Pediatric coronavirus disease-2019-associated multisystem inflammatory syndrome

Cutaneous manifestations of COVID-19: report of three cases and a review of literature

Cutaneous manifestations in COVID-19: a skin rash in a child

Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature

Anosmia and ageusia: common findings in COVID-19 patients

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

Epub ahead of print. 82. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensinconverting enzyme 2 in children and adults

Many faces of renin-angiotensin systemfocus on eye

This study was partially supported by Brazilian National Council of Research 

Vomiting (n = 44), diarrhea (n = 40), abdominal pain (n = 33), lips and oral cavity changes (n = 16), pharyngeal erythema (n = 7), reduced feeding (n = 5), odynophagia (n = 3), vomiting or diarrhea (n = 2), swollen tongue (n = 1), pronounced lingual papillae (n = 1), pharyngeal congestion (n = 1), feeding intolerance (n = 1), other non-specified gastrointestinal symptoms (n = 54)

Acute kidney injury (n = 39), uraemia (n = 26), haematuria (n = 13), proteinuria (n = 5), renal failure (n = 2), oliguria (n = 2), prerenal acute renal failure (n = 1), elevated creatinine (n = 1) 13.9%

Shock (n = 25), elevated myocardial enzymes (n = 11), tachycardia (n = 8), moderate coronary artery dilations (n = 5), cardiac injury and mild to moderate cardiac dysfunction (n = 5), midbasal hypokinesis of the inferoseptal wall and inferior wall (n = 4), hypotension (n = 3), hypotensive shock (n = 1), compensated shock (n = 1), left anterior descending artery aneurysm (n = 1), right coronary aneurysm (n = 1), mildly abnormal myocardial zymogram (n = 1), myocardia injury (n = 1), right MCA and ACA ischaemic infarction (n = 1), myocarditis (n = 1), cardiac arrest (n = 1), atrial fibrillation (n = 1), miocardial damage (n = 1), mitral valve regurgitation (n = 1)

Kawasaki disease Complete Kawasaki disease (n = 42), Kawasaki disease shock syndrome (n = 28) 10.9%

Multisystem inflammatory syndrome (n = 24), elevated C-reactive protein level (n = 22), systemic inflammatory response (n = 3), arthralgia (n = 2), multiple organ dysfunction syndrome (n = 2), severe inflammatory response (n = 1), high levels of inflammatory markers (n = 1), mildly elevated alkaline and phosphatase and calcium (n = 1), lactate dehydrogenase elevated (n = 1), severe lactic acidosis (n = 1), hypothermia (n = 1), elevated creatine kinase isoenzyme (n = 1), elevated serum levels of creatine kinase (n = 1)

Neurocognitive symptoms (n = 19; headache, irritability, lethargy), irritability (n = 14), headache (n = 5), asthenia (n = 3), somnolence (n = 2), axial hypotonia (n = 2), slight fussiness (n = 1), upward rolling of the eyes (n = 1), increasing lethargy (n = 1), muscle pain (n = 1), generalized hypertonia (n = 1), leg pain (n = 1), other non-specified neurological symptoms (n = 8)

J o u r n a l P r e -p r o o f

Cervical lymphadenopathy (n = 12), lymphopenia (n = 12), leucopenia (n = 8), neutrophilia (n = 2), neutropenia (n = 1), monocytosis (n = 1), leukocytosis (n = 1), eosinopenia (n = 1), elevated erythrocyte sedimentation rate (n = 1)

Cutaneous Skin rash (n = 13), perineal or face desquamation (n = 4), exanthema (n = 2), periorbital erythema (n = 1), mottling (n = 1), erythema (n = 1) 3.4%

Acute liver injury (n = 7), liver enzymes elevated (n = 2), cholestasis (n = 1), alterations in hepatic function measures (n = 1), slight increase in transaminase and gamma-GT (n = 1) 1.9%

Watery eye discharge (n = 1), periorbital erythema (n = 1), conjunctivitis (n = 1), non-exudative conjunctivitis (n = 1) 0.6%

Anosmia (n = 2), ageusia (n = 1) 0.5%